CellCentric completes $220 million Series D financing led by Venrock Healthcare to advance inobrodib trials for multiple myeloma.
Amount Raised
$220 Million
Round Type
Series D
CambridgeManufacturingBiotechnologyHealth CareInvestors
Description
CellCentric has announced an oversubscribed $220 million Series D financing to support pivotal trials of inobrodib. The financing was led by Venrock Healthcare Capital Partners and included participation from various investors. Proceeds will fund the Phase 2 DOMMINO-1 and Phase 3 DOMMINO-2 trials. The CEO emphasizes the significant unmet need in treatments for multiple myeloma.
Quick answer
CellCentric raised $220 Million in a Series D round, dated May 6, 2026. Investors: Avego Bioscience Capital, American Cancer Society BrightEdge, Forbion, Fidelity Management & Research Company, Sofinnova Partners, Hbm Healthcare, RA Capital Management and Pfizer. CellCentric is based in Cambridge, England, United Kingdom.
- How much did CellCentric raise?
- CellCentric raised $220 Million in a Series D round on May 6, 2026.
- Who invested in CellCentric?
- Avego Bioscience Capital, American Cancer Society BrightEdge, Forbion, Fidelity Management & Research Company, Sofinnova Partners, Hbm Healthcare, RA Capital Management and Pfizer are named as investors in this round.
- What does CellCentric do?
- CellCentric is a clinical-stage biotechnology company advancing Inobrodib, a new treatment for cancer, particularly multiple myeloma.
- Where is CellCentric based and how big is it?
- CellCentric is based in Cambridge, England, United Kingdom. Fundz records about 52 employees.
- Who are the decision-makers at CellCentric?
- Fundz holds 1 contact at CellCentric. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Manufacturing and Biotechnology around the same time
Companies in the same sectors as CellCentric that raised within 45 days of this round, from Fundz verified event records.
- RedHill Biopharma Ltd raised $6M (Post-IPO Equity) on June 18, 2026.
- Icarus Medical raised $7.2M (Series A) on June 17, 2026.
- IceCure Medical raised $17M on June 17, 2026.
- Nanordica Medical raised $1.8M (Seed) on June 10, 2026.
- NVENTRIC raised $23M on June 10, 2026.
- FesariusTherapeutics raised $20M (Series A) on June 10, 2026.
Who to call at CellCentric, and when
A new round usually means CellCentric is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day CellCentric raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at CellCentric, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CellCentric. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment CellCentric raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
CellCentric raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.